ILMN
Illumina, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers):
breedte van houders -4.2% ·
aandelenstroom +4.1% ·
netto nieuwe posities -8.7%
— formule
Geconcentreerde accumulatie — stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 162 | +8 | 116.88M | $20.55B | +11 | −4 |
| Q1 2026 | 158 | -5 | 113.90M | $14.03B | +5 | −11 |
| Q4 2025 | 162 | 0 | 124.91M | $16.38B | +2 | −1 |
| Q3 2025 | 23 | -1 | 78.13M | $7.41B | +1 | −3 |
| Q2 2025 | 22 | 0 | 71.58M | $6.83B | +1 | −1 |
| Q1 2025 | 19 | 0 | 39.00M | $3.09B | +1 | −1 |
| Q4 2024 | 19 | 0 | 37.37M | $4.99B | +2 | −2 |
| Q3 2024 | 18 | 0 | 20.75M | $2.70B | +1 | −1 |
| Q2 2024 | 18 | — | 22.19M | $2.32B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 19.98M | +20.0% | $1.90B | 0.3% | ▲ Add | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passief) | 18.69M | -3.5% | $1.77B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 3 | The Vanguard Group ✦ (passief) | 14.63M | -3.5% | $1.39B | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 4 | State Street Global Advisors ✦ (passief) | 6.00M | +6.8% | $569.80M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 3.40M | +3.1% | $315.91M | 0.2% | ▲ Add | 6 | SEC ↗ ×7 |
| 6 | Geode Capital Management ✦ (passief) | 2.74M | -4.5% | $259.30M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | PRIMECAP Management ✦ | 1.89M | -3.7% | $179.04M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 8 | Baillie Gifford ✦ | 1.69M | -3.1% | $160.19M | 0.1% | ▼ Trim | 6 | SEC ↗ ×4 |
| 9 | JPMorgan Chase ✦ | 1.67M | — | $158.16M | 0.0% | n/c | 1 | SEC ↗ ×28 |
| 10 | Fidelity (FMR) ✦ | 1.57M | +39.2% | $149.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 11 | Morgan Stanley ✦ | 1.52M | — | $144.69M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 12 | ARK Investment Management ✦ | 1.47M | +25.7% | $139.40M | 0.8% | ▲ Add | 4 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 1.20M | +17.9% | $114.43M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 14 | Goldman Sachs Group ✦ | 501.50K | — | $47.63M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 15 | Millennium Management ✦ | 330.74K | +172.2% | $31.41M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 292.69K | +97.5% | $27.80M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 227.64K | -32.0% | $21.62M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 129.56K | +7.2% | $12.30M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 19 | Glenview Capital ✦ | 101.72K | Nieuw | $9.66M | 0.2% | New | 1 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 44.40K | -80.5% | $4.22M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 42.80K | +59.2% | $4.07M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 22 | Wellington Management ✦ | 21.11K | -28.3% | $2.00M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 23 | D. E. Shaw & Co. ✦ | 9.78K | -45.1% | $929,186 | 0.0% | ▼ Trim | 6 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Glenview Capital | $9.66M | 0.2% |
Verlaten
| Duquesne Family Office | $28.68M | was 0.7% |
| Norges Bank | $22.86M | was 0.0% |
| Marshall Wace | $5.69M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 837 houders, 154.80M aandelen, $18.58B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 7.50K aand · $1.63M
Director · 11.35K aand · $2.49M
Director · 100.65K aand · $21.98M
Director · 13.26K aand · $2.87M
Director · 9.96K aand · $2.21M
Director · 6.66K aand · $1.47M
Director · 13.72K aand · $3.01M
Director · 9.72K aand · $2.12M
Director · 14.20K aand · $3.08M
Director · 8.44K aand · $1.82M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie